NEW PROSPECTS OF ANTITHROMBOTIC THERAPY IN PATIENTS WITH ATRIAL FIBRILLATIO AND CORONARY ARTERY STENTS: DABIGATRAN POTENTIAL
After percutaneous coronary intervention, patients receive double antiplatelet therapy for several months, which includes acetylsalicylic acid and a P2Y12 receptor inhibitor. In most cases, managing the patients with the atrial fibrillation requires adding an anticoagulant drug to the antiplatelet t...
Saved in:
| Main Authors: | M. Yu. GILYAROV, E. V. KONSTANTINOVA |
|---|---|
| Format: | Article |
| Language: | Russian |
| Published: |
«REMEDIUM GROUP» Ltd.
2017-12-01
|
| Series: | Атеротромбоз |
| Subjects: | |
| Online Access: | https://www.aterotromboz.ru/jour/article/view/131 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
STRATEGY TO MINIMIZE THE BLEEDING RISKS IN PATIENTS WITH ATRIAL FIBRILLATION WHO RECEIVE COMBINED ANTITHROMBOTIC THERAPY AFTER PERCUTANEOUS CORONARY INTERVENTION
by: D. A. Zateishchikov
Published: (2018-05-01) -
Modern strategy of antithrombotic therapy in patients with coronary artery disease and atrial fibrillation after percutaneous coronary intervention
by: Yu. A. Karpov
Published: (2019-12-01) -
THE SPECIFICS OF PRESCRIBING TRIPLE ANTITROMBOTIC THERAPY WITH RIVAROXABAN IN PATIENTS WITH ATRIAL FIBRILLATION AFTER CORONARY ARTERY STENTING
by: N. A. Novikova, et al.
Published: (2017-05-01) -
Dabigatran etexilate in patients with nonvalvular atrial fibrillation: benefits of application in certain clinical situations
by: E. I. Baranova, et al.
Published: (2019-11-01) -
CLINICAL IMPRESSION: PLANNED PERCUTANEOUS CORONARY INTERVENTION IN A PATIENT WITH ATRIAL FIBRILLATION
by: Andrei I. Komarov
Published: (2018-12-01)